OncoTherapy Science (4564) · InitiativeFirst stated

Launch of the ImmunoOnco Genomics® brand

First written in FY2027-H1. . Latest entry: FY2027-H1.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Advancing Personalized Healthcare and Cancer Genomic MedicineA theme 4 companies write about · 0 as a headwind · 11 as a tailwind

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Full recordFilings, disclosures and news, newest first

FY2027-H1First statedAnnual report
「CPM launched “ImmunoOnco Genomics®” (イムノオンコ・ゲノミクス, abbreviated as IOG) as a brand representing genomic analysis in the fields of cancer and immunology. The concept of “ImmunoOnco Genomics®” is to combine expertise in cancer and immunology with advanced genomic analysis technologies to deliver new value in both clinical and research settings. CPM is committed to providing high-quality analytical services that support advances in research and medicine.」
CPM launched “ImmunoOnco Genomics®,” an analytical services brand that combines expertise in cancer and immunology with genomic analysis technologies.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for OncoTherapy Science yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.